The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies

Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy

(2011) Madelaine Niam et al.   EXPERIMENTAL HEMATOLOGY

Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies

(2010) A. Pievani et al.   BLOOD

Extramedullary relapses after allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

(2010) W. B. Clark et al.   HAEMATOLOGICA

NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia

(2010) Jeffrey E. Rubnitz et al.   JOURNAL OF CLINICAL ONCOLOGY

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

(2008) R. Nishimura et al.   BLOOD

Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell

(2008) Yeh C. Linn et al.   IMMUNOLOGY

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma

(2007) Adrian J.C. Bloor et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION